MediWound (NASDAQ:MDWD) Share Price Passes Above 50 Day Moving Average - Time to Sell?

Key Points

• MediWound Ltd. shares rose above their fifty-day moving average ($17.64), with the stock trading as high as $19.49 and last recorded at $18.80.
• Despite a consensus rating of "Hold", multiple analysts have downgraded the stock recently, with Weiss Ratings issuing a "sell" rating and Zacks Research dropping it to a "strong sell."
• MediWound reported a loss of ($1.23) EPS for the last quarter, missing analysts' expectations, and has a current market capitalization of $208.44 million.

MediWound Ltd. (NASDAQ:MDWD - Get Free Report) shares crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $17.64 and traded as high as $19.49. MediWound shares last traded at $18.80, with a volume of 60,146 shares trading hands.

Wall Street Analysts Forecast Growth

MDWD has been the topic of a number of research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of MediWound in a report on Wednesday, October 8th. Wall Street Zen lowered MediWound from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Finally, Zacks Research lowered MediWound from a "hold" rating to a "strong sell" rating in a report on Monday, October 13th. Four investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, MediWound currently has a consensus rating of "Hold" and a consensus price target of $32.25.

MediWound Price Performance

The business has a fifty day moving average of $17.64 and a 200-day moving average of $18.57. The stock has a market capitalization of $208.44 million, a price-to-earnings ratio of -7.12 and a beta of 0.27.

MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.68). The firm had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%. As a group, research analysts anticipate that MediWound Ltd. will post -2.66 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MDWD. Silverberg Bernstein Capital Management LLC grew its holdings in MediWound by 41.9% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 147,535 shares of the biopharmaceutical company's stock worth $2,858,000 after acquiring an additional 43,591 shares during the period. Sheets Smith Investment Management purchased a new position in MediWound in the 3rd quarter worth about $362,000. Menora Mivtachim Holdings LTD. purchased a new position in MediWound in the 2nd quarter worth about $339,000. Marshall Wace LLP purchased a new position in MediWound in the 2nd quarter worth about $317,000. Finally, Jane Street Group LLC purchased a new position in MediWound in the 2nd quarter worth about $295,000. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.